Belzutifan Patent Expiration
Belzutifan is Used for treating advanced renal cell carcinoma after previous treatment with specific inhibitors. It was first introduced by Merck Sharp And Dohme Corp A Sub Of Merck And Co Inc
Belzutifan Patents
Given below is the list of patents protecting Belzutifan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Welireg | US12358870 | Solid Dispersions And Pharmaceutical Compositions Comprising A Substituted Indane And Methods For The Preparation And Use Thereof | Jun 30, 2042 | Merck Sharp Dohme |
| Welireg | US10335388 | Combination Therapy Of A Hif-2-Alpha Inhibitor And An Immunotherapeutic Agent And Uses Thereof | Apr 14, 2036 | Merck Sharp Dohme |
| Welireg | US9908845 | Aryl ethers and uses thereof | Sep 05, 2034 | Merck Sharp Dohme |
| Welireg | US9969689 | Aryl ethers and uses thereof | Sep 05, 2034 | Merck Sharp Dohme |
| Welireg | USRE49948 | Aryl ethers and uses thereof | Sep 05, 2034 | Merck Sharp Dohme |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Belzutifan's patents.
Latest Legal Activities on Belzutifan's Patents
Given below is the list recent legal activities going on the following patents of Belzutifan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Aug, 2025 | US9908845 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US9969689 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US9908845 |
| transaction for FDA Determination of Regulatory Review Period | 11 Dec, 2023 | US9908845 |
| transaction for FDA Determination of Regulatory Review Period | 11 Dec, 2023 | US9969689 |
| Second letter to regulating agency to determine regulatory review period | 30 May, 2023 | US9908845 |
| Second letter to regulating agency to determine regulatory review period | 30 May, 2023 | US9969689 |
| Letter from FDA or Dept of Agriculture re PTE application | 13 Sep, 2022 | US9969689 |
| Letter from FDA or Dept of Agriculture re PTE application | 13 Sep, 2022 | US9908845 |
| Patent Term Extension (156) Dismissed Critical
| 12 Jan, 2022 | US9969689 |
Belzutifan's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Belzutifan:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
